Author Archives: Oxford Biomedica

LentiVector platform: The first and leading commercial lentiviral-based gene delivery system

Oxford Biomedica’s LentiVector platform, which delivered the first FDA and EMA approved CAR-T cell therapy, enables the successful development of breakthrough gene and cell-based medicines. Discover more about the platform and our long and broad clinical and commercial track record, which spans over 25 years. Oxford Biomedica’s LentiVector platform enables the successful development of breakthrough gene and cell-based medicines. We have a long and broad clinical and commercial track record in the gene therapy field spanning over 25 years. Our…